Research Interests:
- Preclinical development of new therapeutics for Acute Myeloid Leukemia (AML)
- Mechanisms of resistance to tyrosine kinase inhibitors in AML
- Translational/clinical pharmacology of anticancer agents in laboratory models and cancer patients
The research in Dr. Baker’s lab is focused on identifying mechanisms of drug resistance in Acute Myeloid Leukemia (AML) and the preclinical evaluation of new therapeutic strategies to treat or circumvent resistance. These studies utilize molecular biology, pharmacology and next generation sequencing techniques and in vitro/in vivo models of cancer. Her research also involves characterizing the clinical pharmacology of investigational and approved anticancer agents in laboratory models and cancer patients to improve drug therapy. Dr. Baker’s lab works in a collaborative team environment so that the most promising preclinical findings are translated to clinical trials, and in turn, clinical observations provide feedback to inform preclinical studies.
Biosketch:
Dr. Baker received her PharmD degree from the University of California at San Francisco, and her PhD degree in Medicine from the Erasmus University. She was an Assistant Professor of Oncology at Johns Hopkins University and then an Associate Member in the Department of Pharmaceutical Sciences at St. Jude Children’s Research Hospital before moving to The Ohio State University (OSU) in 2015. Dr. Baker currently holds the Gertrude Parker Heer Chair in Cancer Research, and is Professor and Chair of the Division of Pharmaceutics and Pharmacology in the College of Pharmacy, and Associate Director of Shared Resources in the Comprehensive Cancer Center at OSU. She has authored over 190 peer-reviewed articles. She has served on multiple NIH Study Section and Review Panels and recently rotated off as a chartered member of the Developmental Therapeutics Study Section at the NCI. She has held editorial board appointments with various journals such as the Journal of Clinical Oncology. Dr. Baker has mentored over 40 postdoctoral PhD, PharmD and MD researchers and professional, graduate and undergraduate students, with many of them now working at academic institutions and in industry.
Trainees:
Nadeen Anabtawi, PharmD, MSc – Graduate Student
Jack Stromatt – Graduate Student
Recent Publications:
Baker SD, Bates SE, Brooks GA, Dahut WL, Diasio RB, El-Deiry WS, Evans WE, Figg WD, Hertz DL, Hicks JK, Kamath S, Kasi PM, Knepper TC, McLeod HL, O’Donnell PH, Relling MV, Rudek MA, Sissung TM, Smith DM, Sparreboom A, Swain SM, Walko CM. DPYD Testing: Time to Put Patient Safety First. J Clin Oncol. 2023 May 20;41(15):2701-2705. doi: 10.1200/JCO.22.02364. Epub 2023 Feb 23.
Bhatnagar B, Kohlschmidt J, Orwick SJ, Buelow DR, Fobare S, Oakes CC, Kolitz JE, Uy G, Stock W, Powell BL, Nicolet D, Hertlein EK, Mrózek K, Blachly JS, Eisfeld AK, Baker SD*, Byrd JC*. Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study. Blood Adv. 2023 Aug 22;7(16):4671-4675. doi: 10.1182/bloodadvances.2023010482. *Co-senior authors
Kagan AB, Garrison DA, Anders NM, Webster JA, Baker SD, Yegnasubramanian S, Rudek MA. DNA methyltransferase inhibitor exposure-response: Challenges and opportunities. Clin Transl Sci. 2023 Aug;16(8):1309-1322. doi: 10.1111/cts.13548. Epub 2023 Jun 21.
Li Y, Drabison T, Nepal M, Ho RH, Leblanc AF, Gibson AA, Jin Y, Yang W, Huang KM, Uddin ME, Chen M, DiGiacomo DF, Chen X, Razzaq S, Tonniges JR, McTigue DM, Mims AS, Lustberg MB, Wang Y, Hummon AB, Evans WE, Baker SD, Cavaletti G, Sparreboom A, Hu S. Targeting a xenobiotic transporter to ameliorate vincristine-induced sensory neuropathy. JCI Insight. 2023 Jul 24;8(14):e164646. doi: 10.1172/jci.insight.164646. (IF, 8.04)
Persaud AK, Bernier MC, Massey MA, Agrawal S, Kaur T, Nayak D, Xie Z, Weadick B, Raj R, Hill K, Abbott N, Joshi A, Anabtawi N, Bryant C, Somogyi A, Cruz-Monserrate Z, Amari F, Coppola V, Sparreboom A, Baker SD, Unadkat JD, Phelps MA, Govindarajan R. Increased renal elimination of endogenous and synthetic pyrimidine nucleosides in concentrative nucleoside transporter 1 deficient mice. Nat Commun. 2023 Jun 1;14(1):3175. doi: 10.1038/s41467-023-38789-8. (IF, 16.6)
Talebi Z, Jin Y, Baker SD, Addison D, Sparreboom A. Determination and disposition of meta-iodobenzylguanidine in plasma and heart of transporter-deficient mice by UPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2023 May 1;1222:123699. doi: 10.1016/j.jchromb.2023.123699. Epub 2023 Apr 7. (IF, 3.318)
Buelow DR, Bhatnagar B, Orwick S, Jeon JY, Eisenmann ED, Stromatt JC, Pabla N, Blachly JS, Baker SD*, Blaser BW*. BMX kinase mediates gilteritinib gesistance in FLT3-mutated AML through microenvironmental factors. Blood Adv. 2022 Sep 13;6(17):5049-5060. doi: 10.1182/bloodadvances. 2022007952. *Co-senior authors
Eisenmann ED, Talebi Z, Sparreboom A, Baker SD. Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions. Basic Clin Pharmacol Toxicol. 2022 Jan;130 Suppl 1(Suppl 1):23-35. doi: 10.1111/bcpt.13623. Epub 2021 Jun 28.
Eisenmann ED, Garrison DA, Talebi Z, Jin Y, Silvaroli JA, Kim J-G, Sparreboom A, Savona MR, Mims AS, Baker SD. Interaction of antifungal drugs with CYP3A-and OATP1B-mediated venetoclax elimination. Pharmaceutics. 2022 Mar 23;14(4):694. doi: 10.3390/pharmaceutics14040694.
Eisenmann ED, Stromatt JC, Fobare S, Huang KM, Buelow DR, Orwick S, Jeon JY, Weber RH, Larsen B, Mims AS, Hertlein E, Byrd JC, Baker SD. TP-0903 Is active in preclinical models of acute myeloid leukemia with TP53 mutation/deletion. Cancers. 2022 Dec 21;15(1):29. doi: 10.3390/cancers 15010029. (IF, 6.32)
Garrison DA, Jin Y, Talebi Z, Hu S, Sparreboom A, Baker SD, Eisenmann ED. Itraconazole-induced increases in gilteritinib exposure are mediated by CYP3A and OATP1B. Molecules. 2022 Oct 12;27(20):6815. doi: 10.3390/molecules27206815.
Gartrell J, Panetta JC, Baker SD, Chen YL, Hawkins DS, Ostrenga A, Scharschmidt TJ, Spunt SL, Wang D, Weiss AR. The effects of pazopanib on doxorubicin pharmacokinetics in children and adults with non-rhabdomyosarcoma soft tissue sarcoma: a report from Children’s Oncology Group and NRG Oncology study ARST1321. Cancer Chemother Pharmacol. 2022 Apr;89(4):551-557. doi: 10.1007/s00280-022-04397-4.
Inaba H, van Oosterwijk JG, Panetta JC, Li L, Buelow DR, Blachly JS, Shurtleff S, Pui C-H, Ribeiro RC, Rubnitz JE, Pounds S, Baker SD. Preclinical and pilot study of type I FLT3 tyrosine kinase inhibitor, crenolanib, with sorafenib in acute myeloid leukemia and FLT3-internal tandem duplication. Clin Cancer Res. 2022 Jun 13;28(12):2536-2546. doi: 10.1158/1078-0432.CCR-21-4450.
Stephens D, Ying H, Stark A, Walker J, Canfield D, Cempre C, Baker S, Boyu H, Shah H, Vadeboncoeur R, Rogers K, Bhat S, Jaglowski S, Lockman H, Lapalombella R, Byrd JC, Woyach J. “Selinexor combined with ibrutinib demonstrates tolerability and safety in advanced B-cell malignancies: A phase I study.”Clin Cancer Res. 2022 Aug 2;28(15):3242-3247. doi: 10.1158/1078-0432.CCR-21-3867.
Buelow, Daelynn R., Bhavana Bhatnagar, Shelley J. Orwick, Jae Yoon Jeon, Eric D. Eisenmann, Jack C. Stromatt, Navjot Singh Pabla, James S. Blachly, Sharyn D. Baker, and Bradley W. Blaser. “BMX Kinase Mediates Gilteritinib Resistance in FLT3-mutated AML through Microenvironmental Factors.” Blood Advances (2022). https:/doi: 10.1182/bloodadvances.2022007952
Inaba, H., van Oosterwijk, J. G., Panetta, J. C., Li, L., Buelow, D. R., Blachly, J. S., … & Baker, S. D. (2022). Preclinical and pilot study of type I FLT3 tyrosine kinase inhibitor, crenolanib, with sorafenib in acute myeloid leukemia and FLT3-internal tandem duplication. Clinical Cancer Research : an official journal of the American Association for Cancer Research. (2022) https://doi.org/10.1158/1078-0432.CCR-21-4450
Eisenmann, Eric D., Dominique A. Garrison, Zahra Talebi, Yan Jin, Josie A. Silvaroli, Jin-Gyu Kim, Alex Sparreboom, Michael R. Savona, Alice S. Mims, and Sharyn D. Baker. “Interaction of Antifungal Drugs with CYP3A-and OATP1B-Mediated Venetoclax Elimination.” Pharmaceutics 14, no. 4 (2022): 694. https://doi.org/10.3390/pharmaceutics14040694
Gartrell, J., J. C. Panetta, S. D. Baker, Y. L. Chen, D. S. Hawkins, A. Ostrenga, T. J. Scharschmidt, S. L. Spunt, D. Wang, and A. R. Weiss. “The effects of pazopanib on doxorubicin pharmacokinetics in children and adults with non-rhabdomyosarcoma soft tissue sarcoma: a report from Children’s Oncology Group and NRG Oncology study ARST1321.” Cancer chemotherapy and pharmacology 89, no. 4 (2022): 551-557. https://doi.org/10.1007/s00280-022-04397-4